Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling
暂无分享,去创建一个
J. N. van den Anker | C. Knibbe | Pyry A. J. Välitalo | K. Allegaert | S. Simons | J. Mouton | Catherine M Sherwin | R. F. W. De Cock | Esther J. H. Janssen
[1] Johan W Mouton,et al. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. , 2015, The Journal of antimicrobial chemotherapy.
[2] M. Papas,et al. A Randomized Trial of Loading Vancomycin in the Emergency Department , 2015, The Annals of pharmacotherapy.
[3] C. Knibbe,et al. Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections , 2014, Expert review of anti-infective therapy.
[4] K. V. Van Meurs,et al. Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates , 2014, Antimicrobial Agents and Chemotherapy.
[5] A. Smits,et al. Prospective validation of neonatal vancomycin dosing regimens is urgently needed , 2014, Current therapeutic research, clinical and experimental.
[6] M. Danhof,et al. Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration , 2014, Pharmaceutical Research.
[7] Yook-Hwan Noh,et al. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin‐resistant Staphylococcus aureus by modeling and simulation , 2014, Journal of clinical pharmacy and therapeutics.
[8] A. Baruchel,et al. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease , 2014, Antimicrobial Agents and Chemotherapy.
[9] D. Tibboel,et al. Evidence-Based Morphine Dosing for Postoperative Neonates and Infants , 2014, Clinical Pharmacokinetics.
[10] D. Tibboel,et al. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling , 2013, Archives of Disease in Childhood.
[11] M. Monuteaux,et al. A Randomized Controlled Trial of a Vancomycin Loading Dose in Children , 2013, The Pediatric infectious disease journal.
[12] B. Guglielmo,et al. Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections , 2013, The Pediatric infectious disease journal.
[13] V. Biran,et al. Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates , 2013, Clinical Pharmacokinetics.
[14] E. Capparelli,et al. Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure , 2013, The Pediatric infectious disease journal.
[15] V. Biran,et al. External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings. , 2013, British journal of clinical pharmacology.
[16] A. Thomson,et al. Continuous infusion of vancomycin in neonates , 2013, Archives of Disease in Childhood.
[17] V. Biran,et al. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring , 2012, Archives of Disease in Childhood.
[18] P. Ambrose,et al. Evaluation of a pediatric continuous-infusion vancomycin therapy guideline. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[19] M. Danhof,et al. Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance , 2012, Clinical Pharmacokinetics.
[20] M. Danhof,et al. Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults , 2012, Therapeutic drug monitoring.
[21] G. Giachetto,et al. Vancomycin pharmacokinetic–pharmacodynamic parameters to optimize dosage administration in critically ill children , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[22] Tsz-Yin So,et al. An Evaluation of Initial Vancomycin Dosing in Infants, Children, and Adolescents , 2011, International journal of pediatrics.
[23] L. Benet,et al. Impact of a Hospitalwide Increase in Empiric Pediatric Vancomycin Dosing on Initial Trough Concentrations , 2011, Pharmacotherapy.
[24] Meindert Danhof,et al. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? , 2011, International journal of pharmaceutics.
[25] Thomas M. English,et al. Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients , 2011, The Annals of pharmacotherapy.
[26] C. Oudin,et al. Vancomycin prescription in neonates and young infants: toward a simplified dosage , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.
[27] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] E. Hey. Neonatal Formulary 6: Drug Use in Pregnancy and the First Year of Life , 2011 .
[29] J. Peris,et al. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. , 2010, British journal of clinical pharmacology.
[30] A. Martín-Suárez,et al. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. , 2010, British journal of clinical pharmacology.
[31] B. Charles,et al. Population Pharmacokinetics of Vancomycin in Premature Malaysian Neonates: Identification of Predictors for Dosing Determination , 2010, Antimicrobial Agents and Chemotherapy.
[32] M. Danhof,et al. The role of population PK–PD modelling in paediatric clinical research , 2010, European Journal of Clinical Pharmacology.
[33] L. Benet,et al. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. , 2010, Clinical therapeutics.
[34] L. Benet,et al. Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant Staphylococcus aureus Infections Is Inadequate , 2009, The Pediatric infectious disease journal.
[35] Meindert Danhof,et al. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. , 2009, Drug discovery today.
[36] M. Coulthard,et al. Human renal function maturation: a quantitative description using weight and postmenstrual age , 2009, Pediatric Nephrology.
[37] France Mentré,et al. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R , 2008, Comput. Methods Programs Biomed..
[38] É. Barbotte,et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule , 2008, Archives of Disease in Childhood Fetal and Neonatal Edition.
[39] F. de Zegher,et al. Renal Drug Clearance in Preterm Neonates: Relation to Prenatal Growth , 2007, Therapeutic drug monitoring.
[40] S. Zinner,et al. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model. , 2007, International journal of antimicrobial agents.
[41] V. Fanos,et al. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety , 2006, Expert opinion on drug safety.
[42] France Mentré,et al. Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide , 2006, Pharmaceutical Research.
[43] L. Weisman,et al. Coagulase-negative staphylococcal infections in the neonate and child: an update. , 2006, Seminars in pediatric infectious diseases.
[44] G. Koren,et al. Ontogeny of drug elimination by the human kidney , 2006, Pediatric Nephrology.
[45] E. Niclas Jonsson,et al. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..
[46] J. N. van den Anker,et al. Vancomycin: pharmacokinetics and administration regimens in neonates. , 2004, Clinical pharmacokinetics.
[47] N. Matsuura,et al. Population Pharmacokinetics of Arbekacin, Vancomycin, and Panipenem in Neonates , 2004, Antimicrobial Agents and Chemotherapy.
[48] Susan M Abdel-Rahman,et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.
[49] W. Craig. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. , 2003, Infectious disease clinics of North America.
[50] J. Connor,et al. The Influences of Renal Function and Maturation on Vancomycin Elimination in Newborns and Infants , 2001, Journal of clinical pharmacology.
[51] R. Schoemaker,et al. Vancomycin population pharmacokinetics in neonates , 2000, Clinical pharmacology and therapeutics.
[52] D. Lebel,et al. A Population Pharmacokinetic Model for Vancomycin in Pediatric Patients and Its Predictive Value in a Naive Population , 2000, Antimicrobial Agents and Chemotherapy.
[53] A. Thomson,et al. Pharmacokinetics and dose requirements of vancomycin in neonates , 1999, Archives of disease in childhood. Fetal and neonatal edition.
[54] T. Iga,et al. Population pharmacokinetics of vancomycin in Japanese pediatric patients. , 1998, Therapeutic drug monitoring.
[55] J. Rozé,et al. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. , 1998, British journal of clinical pharmacology.
[56] R. Schoemaker,et al. Tobramycin population pharmacokinetics in neonates * , 1997 .
[57] R. Brundage,et al. Population pharmacokinetics of vancomycin in neonates , 1994, Clinical pharmacology and therapeutics.
[58] G. Koren,et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants , 1987, Antimicrobial Agents and Chemotherapy.
[59] M. Danhof,et al. A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates , 2013, Pharmaceutical Research.
[60] Evelina Tacconelli,et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. , 2012, The Journal of antimicrobial chemotherapy.
[61] D. Levine,et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[62] N. Holford,et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. , 2007, British journal of clinical pharmacology.
[63] M. Rybak,et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[64] Jerome J. Schentag,et al. Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.
[65] Jane Alcorn,et al. Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants Part I , 2002, Clinical pharmacokinetics.
[66] Jane Alcorn,et al. Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants: Part II , 2002, Clinical pharmacokinetics.